Back to Awarded Treatment Trials
Awarded Trial: 99-151
Grant ID
99-151
Illness
Schizophrenia
Primary Drug/Intervention
Estrogen
Primary Dosage
0.625mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Chakos
Sample Size
21
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
PANSS, HAM-D, Quality of Life Scales
Results
Twenty-one patients were randomized and completed the study. Patients with the lowest estrogen levels at baseline had the greatest psychopathology, suggesting a neuroprotective effect of estrogen. Seventy-five percent of patients had low estrogen levels at baseline, which was correlated with poor scores in verbal memory tasks. Estrogen augmentation was associated with a significant improvement in positive symptoms in both pre- and post-menopausal women.
Publication
N/A
Link
N/A
PI Name
Miranda Chakos
Degree
MD
Center
SUNY Downstate Medical Center
Institution
N/A
Address
450 Clarkson Avenue, Box 1203
City or Town
Brooklyn
State or Province
NY
Zip or Postal Code
11203
Country
USA
Email Address
miranda.chakos@downstate.edu